Total Funding
92
68
Total FundingSeries B raised
Growth Score
1 pts
Heat Score
10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
4919
858 Therapeutics develops small molecule drugs targeting oncology and immunology.
- Jeffrey Stafford: CEO and Founder
- Jim Veal: Chief Scientific Officer
About the Company
858 Therapeutics is a biotechnology company focused on discovering small molecule therapeutics for novel targets in oncology and immunology. The company emphasizes innovative approaches in synthetic lethality, innate immunity, and RNA modulation. Its lead program is a PARG inhibitor currently in early clinical development.
Women Founded
